KRAS and breast carcinoma: miR-143 is down- regulated in CRC tumor samples as compared to normal tissue.[32], [33], [34]KRAS may be a target for miR-143[35] and levels of miR-143 expression in CRC tumour samples are a prognostic biomarker in KRAS wt patients but not a predictive marker for anti-EGFR treatment.[36] Circulating miR-143 has been tested as diagnostic marker in CRC patients, but is not significantly deregulated compared to normal controls.[37] miR-324-3p has not been described in CRC, but is differently expressed in plasma from patients with breast cancer compared to healthy controls.[38].